Adding the clinical framing, because it changes how the question reads.
6 month update on cardiovascular risk: down 60 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.
Dr.PulmRoch said:6 month update on cardiovascular risk: down 60 lbs, off blood pressure meds, A1C normalized.
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].
Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.
These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.
Dr.PulmRoch said:6 month update on cardiovascular risk: down 60 lbs, off blood pressure meds, A1C normalized.
SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].
Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemDr.PulmRoch said:6 month update on cardiovascular risk: down 60 lbs, off blood pressure meds, A1C normalized.
Saving this. It is the first explanation that did not require me to already understand it. Printing the relevant bit and taking it with me.